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Objectives. Westudied long-termeﬀects oftherapy forchildhood lymphomaoncardiac function.Designand patients.W ep r osp e c -
tively evaluated 45 survivors of childhood lymphoma, using clinical parameters, electrocardiography and echocardiography.
Further comparisons were made between lymphoma subgroups and between males and females. Results. Mean age at diagnosis
was 9.1 years. Mean followup duration was 10.9 years. The NYHA functional class was I in 43 patients and II in 2 patients. A
prolonged QTc interval (>0.44msec) was found in 8 patients. Left ventricular (LV) systolic function and compliance were normal
(LVshorteningfraction40±5.6%;cardiacindex2.84±1.13L/min/m2;E/Awav eratio2.5±1.3;mean ±S.D.),LVmasswasnormal
(97 ± 40 grams/m2,m e a n± S.D.). Mitral regurgitation was observed in 7/45 patients (16%). Asymptomatic pericardial eﬀusions
were found in 3/45 (7%) patients. Conclusions. Long-term follow-up shows that most parameters of cardiac function are normal
in survivors of childhood lymphoma. This is likely due to relatively low doses of anthracyclines in modern protocol modalities.
Abnormalities in mitral valve ﬂow, QTc prolongation and in a small proportion of survivors, and functional capacity necessitate
long-term cardiac follow-up of these patients.
1.Introduction
Increased long-term survival following eﬀective treatment
of childhood lymphomas has placed greater emphasis on
residual sequelae of therapy for lymphoma and the impact
o ft h e s es e q u e l a ea st h ec a u s eo ff u r t h e rm o r b i d i t ya n d
mortality. Following treatment of childhood Hodgkin’s
disease, cardiac pathology is second only to neoplasm
as the cause of death in initial survivors [1]. As the
number of cancer survivors increases, so does the number
of patients exposed to therapies toxic to the heart and
lung, including radiation and chemotherapeutic modalities
that employ anthracyclines [2] .T h el i t e r a t u r ei sr e p l e t e
regarding eﬀects of anthracyclines and radiation on the
heart; however, there is still debate regarding the detection
of cardiac sequelae [3], their signiﬁcance [4], and the
relation between diﬀerent treatment modalities and the
development of cardiac sequelae. We hypothesized that
protocols employing anthracyclines and radiation would
adversely aﬀect long-term cardiac function and that these
eﬀects would diﬀer between survivors who received diﬀerent
treatment modalities. We therefore prospectively evaluated
long–term cardiac function in 45 survivors of childhood
lymphomas, using clinical parameters, electrocardiography,2 Cardiology Research and Practice
Table 1: Demographic characteristics of survivors by lymphoma subtype.
HD BL NHNB Total/Average
Males (n)1 4 7 5 2 6
Females (n)1 2 5 2 1 9
Mean age at diagnosis (years) 10.8 7.4 5.5 9.1 (range: 2.1–16.4)
Treatment duration (years) 0.9 0.8 1.7 0.94
Age at follow-up (years) 23.1 19.1 16.7 21 (range: 2.1–16.4)
Followup duration (years) 11.3 10.9 9.5 10.9 (range: 2.1–16.4)
and echocardiography and compared these parameters be-
tween lymphoma subtypes.
2.PatientsandMethods
The study included survivors of histology-diagnosed child-
hood lymphomas who had at least 5 years of followup
from termination of therapy, and who were less than 18
years of age at treatment initiation. These criteria identiﬁed
45 survivors of 108 children treated for lymphoma at the
PediatricHematologyandOncologydepartment ofatertiary
care center during a nineteen-year period. Fifteen additional
survivors meeting these inclusion criteria declined complete
participation in the protocol. All participants underwent
evaluation which included an interview to assess functional
class (New York Heart Association), physical examination,
12-lead electrocardiography (ECG), and echocardiography.
Data were taken from a single assessment at the last available
follow-up.
Informed consent was obtained from all participants or
their legal guardians.
2.1. Statistics. Statistical analysis was performed using a
commercially available package (Sigmastat 5.0 Jandel Sci-
entiﬁc, San Rafael, California). Comparisons between the
diﬀerent lymphoma subgroups were made using one way
ANOVA or the Tukey correction of this test where normality
failed, and where relevant by the Student’s T-test or the
Mann-Whitney rank sum test where normality failed. Sta-
tistical signiﬁcance was set at P<. 05.
2.2. Study Population. Characteristics of the study popu-
lation including treatment duration and mean follow-up
duration are presented in Table 1.
2.3. Treatment Modalities. Tumor characteristics and thera-
peutic modalities are detailed in Table 2.
The BL subgroup was divided between those treated in
earlier years with protocols (COMP) that did not include
anthracyclines (7/12 patients), and those that were treated
more recently (5/12 patients) with protocols (LMB, NCI)
containing anthracyclines. These two subgroups did not
diﬀer signiﬁcantly with regard to age at diagnoses (6.7 ± 3.7;
8.30±5.1years,resp., P = .52)orageatfollow-up(21.2±4.2;
16.1 ± 5.8y e a r s ,P = .1).
The mean dose of doxorubicin (adriamycin), for the
group as a whole was 25mg/m2 per treatment, leading to
a cumulative dose of 150mg/m2 or a total cumulative dose
of 225–250mg.
All participants underwent evaluation which included
an interview to assess functional class (New York Heart
Association (NYHA)), physical examination, 12-lead ECG,
and echocardiography. Cardiovascularphysicalexamination,
ECG, and echocardiography were performed by 2 senior
staﬀ pediatric cardiologists (A. Lorber and Y. Braver).
Analyses of ECG and echocardiography images were then
undertaken in a blinded manner by diﬀerent investigators
( M .F r i e d b e r ga n dI .S o l t ) .S t r o k ev o l u m ew a sc a l c u l a t e d
by multiplying the aortic valve area, measured from the 2-
dimensional echocardiographic longaxis view oftheinternal
aortic diameter at valvular level, with the velocity time
integral (VTI) of aortic ﬂow. Cardiac index (CI) was then
calculated by multiplying this value by heart rate, and
dividing the product by body surface area. Left ventricular
indices were measured by M-mode echocardiography. Left
ventricular mass was calculated by the Devereux method
[5]. Left ventricular diastolic function was assessed from
mitral valve inﬂow Doppler. Mitral regurgitation was graded
according to the routine clinical gradation used in the lab as
none, trivial, mild, moderate or severe. Echocardiographic
data were compared to well-established normal values [6].
Normal values were deﬁned as being within 2 standard
deviations of the mean normal value: for LV ejection
fraction 66 ± 4%, and LV fractional shortening 36 ± 4%,
LV mass index 70.4gram/m2 for males (10–95 percentile
48.5–103gram/m2) and 60.7gram/m2 for females (10–95
percentile 35.6–81gram/m2). Early diastolic mitral inﬂow
velocity (E wave) to late diastolic mitral inﬂow velocity (A
wave) ratio is 1.7 ± 0.4t o2 .5 ± 0.9. Cardiac dimensions
were deﬁned as being within 2 standard deviations of the
normal mean for body surface area. A QTc > 0.44 seconds
was deﬁned as prolonged.
3.Results
3.1.FunctionalCapacityandHistory. Allpatientshadnormal
cardiovascular function prior to initiation of therapy.
The NYHA functional class was class I in 43 patients
(96%)andclassIIin2patients(4%).These2patientsdidnot
have other comorbidities or notable toxic eﬀects on follow-
up. No Raynaud’s phenomenon was reported. No events of
near-syncope, syncope, or sudden death were noted. Clinical
featuresofthecohort asa whole and oftheHodgkin’sdisease
subgroup are shown in Table 3.Cardiology Research and Practice 3
Table 2: Lymphoma characteristics and treatment data of survivors by lymphoma subtype.
Patient Staging Histology ChemoTx Irradiation Total dose (cGy) Mantle dose (cGy)
HL
1 3B NONE MOPP MANTLE 1500 1500
2 2B NS MOPP MANTLE 3000 3000
3 2B NS MOPP MANTLE 4000 4000
4 1A LP MOPP MANTLE 2000 2000
5 2B LP MOPP MANTLE 4000 4000
6 3A MC MOPP/ABVD TOT. NODAL 1650 1500
7 1A NS MOPP MANTLE 2600 2800
8 2A MC MOPP/ABVD MANTLE 2000 2000
9 2B MC MOPP/ABVD MANTLE,INV.Y.SPLEEN 5800 4000
10 2A NS MOPP/ABVD MANTLE 1800 1800
11 3B NS MOPP/ABVD MANTLE,PARAAORTIC 8000 4000
12 2B NS MOPP/ABVD MANTLE,INV.Y 4000 4000
13 2B MC MOPP/ABVD MANTLE 3060 3060
14 3B NS MOPP MANTLE,INV.Y,SPLEEN 5100 2500
15 2A NONE MOPP MANTLE,INV.Y 8400 4400
16 2B-BULKY MC MOPP/ABVD MANTLE 2600 2600
17 3A NS MOPP/ABVD MANTLE 2600 2600
18 2A-BULKY NS MOPP/ABVD MANTLE 4000 4000
19 1A NS MOPP/ABVD MINIMANTLE 3600 3600
20 2A NS MOPP/ABVD MANTLE 3000 3000
21 3B LD MOPP MANTLE,INV.Y 8000 4000
22 2A NS MOPP MANTLE 4000 4000
23 1A LP NONE MANTLE 4000 4000
24 2A NS MOPP/ABVD MANTLE 2600 2600
25 2A NS NONE MANTLE,PARAO,SPLEEN 8000 4000
26 2B-BULKY NS MOPP/ABVD MANTLE 3000 3000
Average 3935 3152
BL
27 NP 6 COMP 0 0
28 ABD 6 NCI 0 0
29 ABD 6 LMB 0 0
30 ABD 6 COMP 0 0
31 ABD 6 COMP 0 0
32 ABD 6 COMP 0 0
33 ABD 6 COM 0 0
34 ABD 6 COMP WHOLE ABDOMEN 1550 0
35 ABD 6 NCI 0 0
36 ABD 6 LMB 0 0
37 NP 6 ACOMP 0 0
38 ABD 6 NCI 4000 0
Average 462 0
NHNB
39 0 7 LSAL2 0 0
40 0 7 LSAL2/COM BRAIN,TOT.LUNG 3600 0
41 0 7 LSAL2 BRAIN,INV.Y 5600 0
42 0 7 COM 0 0
43 0 7 LSAL2 MEDIASTINUM 750 0
44 0 7 LSAL2 MEDIASTINUM 2000 0
45 0 7 COMP BRAIN 2400 0
Average 2050 0
MOPP: nitrogen mustard, oncovin, prednisone, and procarbazine; COM/P: cyclophosphamide,oncovin, and methotrexate/prednisone; ABVD: adriamycin,
bleomycin, vinblastine, and deticen; NCI: national cancer institute; ACOMP: like comp with adriamycine; LSA2L2: norma wollner protocol; LMB: no
abbreviation; NS: nodular sclerosis;LP: lymphocyte predominance; MC: mixed cellularity;LD: lymphocyte depletion.4 Cardiology Research and Practice
Table 3: Electrocardiographic and echocardiographic data of all survivors and the Hodgkins disease subtype.
All Hodgkins disease
Electrocardiography
Heart rate (bpm) (mean ± SD) 77 ±11
PR interval (seconds) (mean ± SD) 0.144 ±0.024
QTc interval (seconds) (mean ± SD) 0.411 ±0.032 0.417± 0.034 N.S
Echocardiography
LV Fractional shortening (%) 40 ±5.63 9 .5 ± 5.6N . S
Cardiac Index (L/min/m2)2 .84 ±1.13 3.4 ±1.03 N.S
LVED (cm) 4.43 ±0.057 N.S
Septal thickness (cm) 0.65 ±0.12 0.65 ± 0.13 N.S
Posterior wall thickness (cm) 0.66 ± 0.10 .67 ± 0.1N . S
LV mass (gm/m2)9 7 ±40 96 ± 38 N.S
E/A wave ratio 2.5 ±1.32 .29 ± 1.09 N.S
Mitral regurgitation (n, %) 7/45 (16) 4/26 (15) N.S
3.2. Electrocardiography. All patients demonstrated normal
sinus rhythm with no bradycardias or tachycardias noted.
The percentage of survivors with a prolonged QTc interval
bylymphomasubgroupisshown inFigure1(a).Aprolonged
QTc interval was not associated with sinoatrial or atrioven-
tricular node dysfunction-conduction anomalies.
Incomplete right bundle branch block was recorded in 4
patients (9%, all diagnoses); complete right bundle branch
block was recorded in 2 patients. No evidence of ischemia or
“strain” was noted on nonstress ECG.
3.3. Echocardiography. Cardiac systolic and diastolic func-
tion was normal or low-normal for the group as a
whole without signiﬁcant diﬀerences between the subgroups
(Table 3).
LV mass and shortening fraction did not correlate
with mantle irradiation dose, QTc interval, or length of
follow-up. Mean LV mass was within normal limits (97 ±
40grams/m2,m e a n± S.D.).LV mass was signiﬁcantly higher
for males as compared to females (all subjects, 112grams
versus 76grams, resp.; P<. 01). There was no signiﬁcant
diﬀerence in shortening fraction between males and females.
Left ventricular end diastolic internal dimensions did not
increase following relatively smaller shortening fraction
values. Cardiac index and mass by lymphoma subgroup are
presented in Figures 1(b) and 1(c), respectively.
Mild mitral regurgitation was observed in 7 of the 45
patients (16%). The percentage of survivors with mitral
regurgitation by subgroup is shown in Figure 1(d).M i t r a l
valve prolapse was recorded in 1 HD survivor. Pulmonary
valve insuﬃciency, more than the accepted physiological
norm, was found in 1 survivor of NHNB.
Asymptomatic small pericardial eﬀusions were found in
3 of the 45 patients (7%). No larger eﬀusions or pericardial
thickening was noted in any of the patients. A mitral inﬂow
pattern consistent with constrictive or restrictive physiology
(elevated E wave velocity, elevated E/A ratio, and short
deceleration time) was not noted in any of the patients.
Selected electrocardiographic and echocardiographic
parameters for the subset of BL survivors treated with
anthracyclines versus those not treated with anthracyclines
are presented in Table 4.
4.Discussion
Cardiac abnormalities described after treatment for child-
hood lymphomas can involve almost any aspect of cardiac
function and include pericarditis, pericardial eﬀusions, peri-
cardial ﬁbrosis, pancarditis, myocardial ﬁbrosis with func-
tional impairment, valvular disease, conduction defects, and
coronary artery disease [1]. Although sequelae may develop
at variable time intervals following treatment, emphasis is
now placed on the long-term sequelae of lymphoma therapy
[7, 8], which are caused mainly by anthracyclines and
radiation [9].
In our study population, most parameters of cardiac
status were within normal limits. This is most likely due to
the relatively low dose of anthracyclines used. Previous study
has shown that an average cumulative dose of 450mg/m2 of
doxorubicin causes a 23% abnormality rate in echocardio-
graphic ﬁndings during a 7-year follow-up period [10]a n d
that sequelae are rare at doses under 300mg/m2 [10, 11].
Our study population received an average of 150mg/m2 of
doxorubicin, leading to a total dose of 225–250mg, which is
less than the average toxic dose. This is achieved in modern
protocols through regimens employing multidrug therapy.
The average follow-up duration for our population was 10.9
years, which is longer than that of many other studies, with
relatively few cardiac sequelaefrom anthracyclines. However,
these patients still warrant long-term cardiac follow-up,
as the risk for cardiomyopathy continues to increase over
time [12, 13]. This vigilance is further justiﬁed by previous
ﬁndings that patients may develop cardiac complications
from anthracyclines, even when lower doses are used [13].
Studies performed 2 to 3 decades ago identiﬁed factors
that augment the cardiotoxicity of anthracyclines. These
include radiation of the mediastinum [14, 15], previous
cardiac abnormalities, including involvement of the heart
by the tumor [16, 17], uncontrolled hypertension [11, 12],
and exposure to other chemotherapy modalities such asCardiology Research and Practice 5
Table 4: Comparison of selected electrocardiographic and echocardiographic characteristics between Burkitt lymphoma survivors who
received or did not receive anthracyclines as part of their treatment regimen.
B.L. patients who received anthracyclines B.L. patients who did not receive anthracyclines
LV shortening fraction (%) 41 ± 53 9 ±3N . S
QTc 0.416 ± 0.03 0.4 ± 0.02 N.S
LV mass 121 ± 36 85 ± 37 N.S
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Figure 1: (a) Percentage of survivors with prolonged QTc interval (>0.44s) among the lymphoma subgroups. (b) Cardiac index among the
lymphoma subgroups. N = 45, Mean + SD, ANOVA P<. 01. (c) Left ventricular mass among the lymphoma subgroups. N = 45, Mean +
SD,ANOVAnotsigniﬁcant.(d)Percentageofsurvivorswith mitralregurgitation amongthelymphomasubgroups. N = 45.H.D.:Hodgkin’s
Disease, B.L.: Burkitt’s Lymphoma,N.H.N.B.: Non Hodgkin Non Burkitt lymphoma.
cyclophosphamide, dactinomycin, mitomycin, vincristine,
bleomycin and methotrexate [13, 18, 19]. Demographic
factors include young age, female sex, black race and also
trisomy 21 [7]. Among these, our study population was
exposed to radiation of up to 4400cGy (but in most
instances less than this) and to polychemotherapy, including
vincristine and bleomycin, as dictated by the various treat-
ment protocols. More recently a pathophysiological role for
t h et y r o s i n ek i n a s er e c e p t o r ,ErbB2, has been implicated in
cardiomyocyte susceptibility to anthracyclines [20].
Again, the total dose of doxorubicin was probably
the most important factor in preventing signiﬁcant cardio
toxicityamong ourpopulation. These ﬁndings are consistent
with otherstudiesthatfoundthatmodernprotocoltherapies
using MOPP/ABVD and radiation hold low risk for cardiac
toxicity [21, 22].6 Cardiology Research and Practice
Leandro et al. [9] suggested that cardiac status following
anthracyclines is described by a pattern consistent with a
thin-walled, compliant left ventricle with reduced muscle
mass performing under above-normal levels of wall stress.
Our results are consistent with this description and show
left ventricular dimensions at the lower level of normal, with
good compliance.
It is surprising that no statistical diﬀerences in systolic
function and left ventricular mass and thickness were found
between the lymphoma type subgroups, in the light of the
substantial diﬀerences in therapy that these groups received.
Although diﬀerences in left ventricular mass between BL
patients who received anthracyclines and those who did
not reach statistical signiﬁcance, our data may correlate
with the aforementioned ﬁndings that anthracyclines reduce
ventricular mass and reduce left ventricular wall thickness.
However, no diﬀerences were found between the various
lymphoma subgroups, among whom HD patients were
exposed both to anthracyclines as well as to radiation.
Indeed, these patients exhibited increased cardiac output in
comparison to the other lymphoma subgroups. We do not
have a clear interpretation for this result. More importantly,
cardiac index was at the low range of normal, or slightly
below normal, for all groups. Diﬀerences between males
and females were signiﬁcant regarding LV mass, a factor
that contributes to the greater susceptibility of females to
anthracyclines [7], and the greater prevalence of prolonged
QTc interval among females.
We found an increased prevalence of mitral valve
regurgitation in our study population. An earlier study
[23] found mitral valve regurgitation in 24% of patients.
The signiﬁcance of mitral valve regurgitation in these
patients is not entirely clear. Minimal mitral insuﬃ-
ciency, in the absence of valve deformity, is usually of
little clinical signiﬁcance [24]. However, Allen et al. [25]
detected an increase in the prevalence of mitral regurgi-
tation among children who had received anthracyclines,
12% (4 of 34) of whom later developed left ventricular
systolic dysfunction, concluding that mitral regurgitation
might be an early marker of anthracycline-related cardiac
dysfunction.
Seventeen percent of the patients we studied demon-
strated a prolonged corrected QT interval. Cardiac dysrhyth-
mias are prevalent in survivors of lymphoma treated with
anthracyclines [26]. Our ﬁndings correlate with those of
previous studies, where both QT and QT dispersion were
prolonged following treatment with anthracyclines [27, 28].
A prolonged QT interval may result from myocardial cell
damage but does not correlate with decreased contractile
function [29, 30]. As dysrhythmias may occur years after
termination of treatment and these are potentially life-
threatening, patients should be evaluated at regular followup
witha12-leadECG[8,31].Althoughnosuddendeathevents
were observed in our population, following our ﬁndings
of a prolonged Q-T interval in a substantial percentage of
the population, it may be suggested that a 24-hour holter-
ECG recording be part of the routine follow-up of these
patients.
Coronary artery disease has been reported after radia-
tion therapy to the mediastinum, but not after anthracy-
cline therapy [1, 32]. This pathology led to signiﬁcantly
increased mortality at 7-year follow-up. Our results did not
show resting ECG changes, and there was no premature
mortality among our study group on a longer follow-
up period. In the light of ﬁndings from other studies,
we would suggest periodic ergometry in the long-term
follow-up of patients who have undergone radiation therapy
[33].
Additional well-described sequelae of radiation therapy
to the mediastinum are pericardial eﬀusion and constrictive
pericarditis [34,35].We didnot note these pathologiesto any
signiﬁcant degree in our study population.
The use of possible cardioprotective agents such as
dexrazoxane mayprovideadditionalprotectionagainst long-
term cardiac sequelae of anthracyclines, especially in girls
[36, 37]. These agents were not used in our study, and we
cannot comment further on their eﬀects.
Limitations. This study has certain limitations. This study
was performed as a retrospective analysis of data with
inherent limitations. The study group is relatively small
and the number of patients in subgroups is small. We
did not compare the study group with a control group,
as our primary objective was deﬁnition of cardiac status
among survivors. However, we used well-established norms
that are commonly and widely used as the basis for
this deﬁnition. Further comparisons between the diﬀerent
lymphoma subgroups, provided a comparative basis for
the diﬀerent treatment modalities, and speciﬁc comparison
between Burkitt lymphoma survivors who had been exposed
to anthracyclines and those who had not strengthened this
comparison. Echocardiographic parameters such as ejection
fraction and fractional shortening are limited by load depen-
dency and constitute basic indicators of global ventricular
function. Although other echocardiographic methods are
available for assessment of cardiac function, each has its
speciﬁc limitations and in daily clinical practice many
oncologistsare more familiar withthetraditional parameters
used in this study. Likewise assessment of left ventricular
mass by echocardiography is limited. This study focused on
long-term follow-up with data collected at the last available
assessment, and we did not collect data on acute or subacute
toxicity.
In summary, in this cohort, relatively few long-term
cardiac complications were seen in most patients following
low-dose anthracycline therapy used in modern treatment
protocols for childhood lymphoma. However, anthracycline
cardio toxicity has previously been well established and
in the current study, abnormalities were found in mitral
valve regurgitation abnormalities, QT prolongation, low-
normal cardiac index, and in 2 survivors functional capac-
ity reduction leading to a compromised quality of life.
The greater frequency of abnormalities in females requires
increased vigilance in this group. These ﬁndings necessitate
comprehensive and long-term cardiac follow-up of these
patients.Cardiology Research and Practice 7
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